SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital
Purpose: Multisystem inflammatory syndrome in children (MIS-C) – the most severe status, associated with SARS-COV-2 infection. Clinical and laboratory characteristics of MIS-C, and treatment optimization are topical problems on current stage. Our aim to analyze main features of the MIS-C. Methods & Materials: We evaluated 41 children (21M/18F) 1 - 16 yrs. (8,45±0,677 yrs.) hospitalized in Khimki Regional Hospital with MIS-C from June 2020 to April 2021. 7 children had background disease (allergy, nephroblastoma, ulcerative colitis, diabetes mellitus, urologic pathology). 5 children were mongoloid race (12%). Excessive weight had 27%, according to BMI; 17% had high growth to age. 58% had A(II) blood group, Rh(+)-positive were 74%. Results: All children at the admission had fever more than 3 days. Anti-SARS-COV-2 IgM and IgG had 1 patient, IgG only - 25 (61%); 2 patients were positive SARS-Cov2 RNA in the oropharyngeal swab; 27% had family contact to СOVID-19. By severity 66% children were hospitalized to the ICU. Clinically skin and mucosal signs had 31 (76 %), gastro-intestinal symptoms – 22 (54%), pneumonia – 20 (49%), kidney injury –15 (40%), cardiovascular damage - 10 (24%), CNS –6 (15%). Simultaneous damage of 2 systems had 37% children, 3 – 46%, 4 - 12%, 5 – 1 patient, 6 – 1 patient. 5 cases developed acute kidney injury like hemolytic-uremic syndrome (HUS), as the main MIS-C performance.Laboratory features: increased ESR (Мe 40,0 (IQR 30-50) мм/ч), elevated CRP (Мe 118,9 (IQR 71,5-129,4)), ferritin (Мe 471,0 (IQR 214,08-990,28)), D-dimer (Мe 2,81 (IQR 1,76 – 4,55)), LDH (Мe 594,0 (IQR 511,0-663,0)), CK (Мe 112,0 (IQR 61,35-288,7)), CK-MB (Мe 44,95 (IQR 33,0-80,1)), decreased albumin (Мe 27,4 (IQR 23,0-33,0)). In 76% patients were treated with methylprednisolone pulse, IVIG in 20%, standard doses of corticosteroids – 10%. All children discharged home with recovery. Conclusion: MIS-C is the most severe form of COVID-19 in children. In Khimki Regional Hospital 41 patient were successfully treated. The main features are severe status (66%-ICU), 63% children had 3+ affected systems; the main symptoms are skin and mucosal damage, gastrointestinal signs and headache, high BMI. There were 5 patients with HUS, during SARS-Cov2 associated MIS-C..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
---|---|
Enthalten in: |
International Journal of Infectious Diseases - 116(2022), Seite S41- |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
D. Novikov [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
---|
doi: |
10.1016/j.ijid.2021.12.099 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ003621707 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ003621707 | ||
003 | DE-627 | ||
005 | 20230502125921.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ijid.2021.12.099 |2 doi | |
035 | |a (DE-627)DOAJ003621707 | ||
035 | |a (DE-599)DOAJacfe9df516a0465399cfc087105b66dd | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC109-216 | |
100 | 0 | |a D. Novikov |e verfasserin |4 aut | |
245 | 1 | 0 | |a SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Purpose: Multisystem inflammatory syndrome in children (MIS-C) – the most severe status, associated with SARS-COV-2 infection. Clinical and laboratory characteristics of MIS-C, and treatment optimization are topical problems on current stage. Our aim to analyze main features of the MIS-C. Methods & Materials: We evaluated 41 children (21M/18F) 1 - 16 yrs. (8,45±0,677 yrs.) hospitalized in Khimki Regional Hospital with MIS-C from June 2020 to April 2021. 7 children had background disease (allergy, nephroblastoma, ulcerative colitis, diabetes mellitus, urologic pathology). 5 children were mongoloid race (12%). Excessive weight had 27%, according to BMI; 17% had high growth to age. 58% had A(II) blood group, Rh(+)-positive were 74%. Results: All children at the admission had fever more than 3 days. Anti-SARS-COV-2 IgM and IgG had 1 patient, IgG only - 25 (61%); 2 patients were positive SARS-Cov2 RNA in the oropharyngeal swab; 27% had family contact to СOVID-19. By severity 66% children were hospitalized to the ICU. Clinically skin and mucosal signs had 31 (76 %), gastro-intestinal symptoms – 22 (54%), pneumonia – 20 (49%), kidney injury –15 (40%), cardiovascular damage - 10 (24%), CNS –6 (15%). Simultaneous damage of 2 systems had 37% children, 3 – 46%, 4 - 12%, 5 – 1 patient, 6 – 1 patient. 5 cases developed acute kidney injury like hemolytic-uremic syndrome (HUS), as the main MIS-C performance.Laboratory features: increased ESR (Мe 40,0 (IQR 30-50) мм/ч), elevated CRP (Мe 118,9 (IQR 71,5-129,4)), ferritin (Мe 471,0 (IQR 214,08-990,28)), D-dimer (Мe 2,81 (IQR 1,76 – 4,55)), LDH (Мe 594,0 (IQR 511,0-663,0)), CK (Мe 112,0 (IQR 61,35-288,7)), CK-MB (Мe 44,95 (IQR 33,0-80,1)), decreased albumin (Мe 27,4 (IQR 23,0-33,0)). In 76% patients were treated with methylprednisolone pulse, IVIG in 20%, standard doses of corticosteroids – 10%. All children discharged home with recovery. Conclusion: MIS-C is the most severe form of COVID-19 in children. In Khimki Regional Hospital 41 patient were successfully treated. The main features are severe status (66%-ICU), 63% children had 3+ affected systems; the main symptoms are skin and mucosal damage, gastrointestinal signs and headache, high BMI. There were 5 patients with HUS, during SARS-Cov2 associated MIS-C. | ||
653 | 0 | |a Infectious and parasitic diseases | |
700 | 0 | |a E. Melekhina |e verfasserin |4 aut | |
700 | 0 | |a T. Sabinina |e verfasserin |4 aut | |
700 | 0 | |a T. Shalbarova |e verfasserin |4 aut | |
700 | 0 | |a S. Cremplevskaya |e verfasserin |4 aut | |
700 | 0 | |a V. Barykin |e verfasserin |4 aut | |
700 | 0 | |a A. Muzyka |e verfasserin |4 aut | |
700 | 0 | |a Z. Ponezheva |e verfasserin |4 aut | |
700 | 0 | |a N. Pshenichnaya |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 116(2022), Seite S41- |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
773 | 1 | 8 | |g volume:116 |g year:2022 |g pages:S41- |
856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2021.12.099 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/acfe9df516a0465399cfc087105b66dd |z kostenfrei |
856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971221009917 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 116 |j 2022 |h S41- |